Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.
Taking Big Steps
MorphoSys' mission
01/08/2020
MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in...
30/07/2020
Invitation to MorphoSys' Second Quarter and First Half 2020 Results...
14/07/2020
MorphoSys' Licensee Janssen Announces Approval of Tremfya (Guselkumab...
20/05/2020
MorphoSys and Incyte Announce the Validation of the European Marketing...
14/05/2020
MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual...
14/05/2020
MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND...
